These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Glutaraldehyde pre-treated human saphenous and umbilical veins as xenogeneic small vessel substitutes and shunts in dogs.
    Author: Harjula A.
    Journal: Ann Chir Gynaecol; 1981; 70(1):11-7. PubMed ID: 7259055.
    Abstract:
    A total of 84 grafts 100 mm in length was inserted as arterial and shunt conduits in 31 mongrel dogs. There were 24 glutaraldehyde pre-treated vein bypass grafts, 15 glutaraldehyde pre-treated vein shunt grafts, 9 fresh, untreated vein bypass grafts, 10 combined teflon-glutaraldehyde pre-treated vein shunt grafts, 11 glutaraldehyde pre-treated umbilical vein shunt grafts, 11 glutaraldehyde pre-treated umbilical vein bypass grafts, 4 dacron mesh covered modified umbilical vein bypass grafts. The internal diamter was 4 mm in all the saphenous vein grafts and in seven of the umbilical vein grafts and 6 mm in all other grafts. After an implantation period of 0.5--2.5 months, 5 of the 24 glutaraldehyde pre-treated saphenous vein bypass grafts were patent, and the rest thrombosed. These grafts were very adherent to surrounding structures. Glutaraldehyde pre-treated saphenous vein shunt grafts occluded within 2.5 months. Combined teflon-glutaraldehyde pre-treated saphenous vein shunt grafts functioned better, 6 of 10 grafts being patent after 4.0--6.0 months. Eight of 9 fresh grafts were thrombosed within one month. Eleven glutaraldehyde pre-treated human umbilical vein bypass grafts were followed up for 5.0 months and both those with a 4 mm internal diameter and those with 6 mm functioned well. Glutaraldehyde pre-treated human umbilical shunt grafts also functioned well up to 5.0 months. Reactive changes were minimal around umbilical grafts.
    [Abstract] [Full Text] [Related] [New Search]